Jakavi 25mg tablets |Ruxolitinib | MHP
JAKAVI 25MG DESCRIPTION Jakavi 25mg belongs to the classification of medications called anti-cancer drugs. Jakavi 25mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 25mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age. Jakavi 25mg tablet is prescription drug provided under supervision of medical oncologist. jakavi 25mg MECHANISM OF ACTION Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JA...